Study of Profound's prostate cancer device gets green light

09/19/2013 | MassDevice.com (Boston)

The FDA has granted Profound Medical investigational device exemption approval to conduct a clinical study of its device that uses real-time MRI guidance and thermal ultrasound to treat patients with localized prostate cancer. The Canadian company plans to start patient enrollment in the trial in late 2013.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC